Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00037765 · ClinicalTrials.gov registry record
Gene Modifiers of Cystic Fibrosis Lung Disease
A clinical trial of Cystic Fibrosis and Lung Diseases, sponsored by University of North Carolina, Chapel Hill.
- Active
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT00037765: Active study of Cystic Fibrosis and Lung Diseases, sponsored by University of North Carolina, Chapel Hill.
NCT00037765 is a study of Cystic Fibrosis and Lung Diseases that is active but no longer recruiting, run by University of North Carolina, Chapel Hill. The registered enrollment target is 600 participants, above the 176-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (241% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00037765, a study of Cystic Fibrosis and Lung Diseases, is active but no longer recruiting, sponsored by University of North Carolina, Chapel Hill.
- ACTIVE NOT RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine genetic modifiers of the severity of cystic fibrosis lung disease.
Primary Outcome
Not applicable. This is not an interventional study.
Conditions Studied
Study Locations (1)
North Carolina
- Marsico Lung Institute - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2001-09 |
| Est. Completion | 2027-07 |
What the registry record for NCT00037765 still lists
NCT00037765 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 176-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (241% higher).
The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT00037765 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00037765 about?
NCT00037765 is a clinical study titled "Gene Modifiers of Cystic Fibrosis Lung Disease". The purpose of this study is to examine genetic modifiers of the severity of cystic fibrosis lung disease.
What is the current status of trial NCT00037765?
This trial is currently active not recruiting. The enrollment target is 600 participants. The study started on 2001-09. Estimated completion is 2027-07.
What conditions does trial NCT00037765 study?
This clinical trial studies the following conditions: Cystic Fibrosis, Lung Diseases.
Who is sponsoring clinical trial NCT00037765?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00037765 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00037765's enrollment target sits among peer trials
600 9th of 169 higher than 161 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
RECRUITING
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Genetics of Insulin and Incretins in Cystic Fibrosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia